


The Fund's investment objective is to provide a total return primarily through active investment in a value style biased portfolio of equity and equity related securities of companies worldwide.
| Name | % Net Assets |
|---|---|
| Royal Dutch Shell | 1.0% |
| Bristol Myers Squibb | 0.8% |
| Roche Holding | 0.7% |
| Merck & Co | 0.7% |
| AstraZeneca | 0.7% |
| Eli Lilly | 0.7% |
| GlaxoSmithKline | 0.7% |
| Lorillard | 0.7% |
| Pfizer | 0.7% |
| Lockheed Martin | 0.7% |
| Key | % Net Assets |
|---|---|
| 1.0% | |
| 0.8% | |
| 0.7% | |
| 0.7% | |
| 96.8% |
| Date | 20-Aug-2025 |
|---|---|
| NAV | 138.40p |
| Currency | GBP |
| Change | -0.20p |
| % | -0.14% |
| YTD change | 11.80p |
| YTD % | 9.32% |
| Fund Inception | 21/12/2005 |
|---|---|
| Fund Manager | n/a |
| TER | 1.69 (20-Jun-2012) |
| Minimum Investment | |
|---|---|
| Initial | n/a |
| Additional | n/a |
| Savings | n/a |
| Charges | |
|---|---|
| Initial | 3.25% |
| Annual Mang't | 1.50% |
| Exit | n/a |
| Name | % |
|---|---|
| No risk data available. | |
You are here: research